324 related articles for article (PubMed ID: 16171951)
1. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Yamagishi S; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
4. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome.
Güçlü F; Ozmen B; Hekimsoy Z; Kirmaz C
Biomed Pharmacother; 2004 Dec; 58(10):614-8. PubMed ID: 15589072
[TBL] [Abstract][Full Text] [Related]
5. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
6. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Nakamura K; Yamagishi S; Inoue H
Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.
Mizukawa M; Ohmori K; Obayashi A; Ishihara Y; Yoshida J; Noma T; Yukiiri K; Kosaka H; Kohno M
Hypertens Res; 2009 Jul; 32(7):617-24. PubMed ID: 19461650
[TBL] [Abstract][Full Text] [Related]
8. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
[TBL] [Abstract][Full Text] [Related]
9. The metabolic syndrome: metabolic changes with vascular consequences.
Wassink AM; Olijhoek JK; Visseren FL
Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A
Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
Schernthaner GH; Schernthaner G
Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
[TBL] [Abstract][Full Text] [Related]
12. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Stefanović V; Antić S
Clin Lab; 2004; 50(5-6):271-8. PubMed ID: 15209435
[TBL] [Abstract][Full Text] [Related]
16. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
Rosenberg DE; Jabbour SA; Goldstein BJ
Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study.
Patel DA; Srinivasan SR; Xu JH; Chen W; Berenson GS
Metabolism; 2006 Nov; 55(11):1551-7. PubMed ID: 17046560
[TBL] [Abstract][Full Text] [Related]
20. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Field KM
Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
